HUMA
Humacyte, Inc.
$1.06
-1.85%
2026-05-08
About Humacyte, Inc.
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
Key Fundamentals
Forward P/E
-5.70
EPS (TTM)
$-0.26
Profit Margin
0.0%
Debt/Equity
2101.83
Price/Book
65.31
Beta
2.31
Market Cap
$232.0M
Avg Volume (10D)
4.8M
Recent Breakout Signals
No recent breakout signals detected for HUMA.
Recent Price Range (60 Days)
60D High
$1.31
60D Low
$0.55
Avg Volume
6.4M
Latest Close
$1.06
Get breakout alerts for HUMA
Sign up for Breakout Scanner to receive daily notifications when HUMA triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Humacyte, Inc. (HUMA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors HUMA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. HUMA operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.